NPS, AstraZeneca end six-year agreement on CNS disorder research

10/10/2007 | CNNMoney

NPS Pharmaceuticals and AstraZeneca have ended a research partnership to develop central nervous system disorder treatments that target metabotropic glutamate receptors. AstraZeneca will pay NPS $30 million to acquire assets related to their work.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD